Protocol Ledger

NCT07219043 · Phase II · RECRUITING

A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation

Interventional Phase II clinical trial protocol NCT07219043 sponsored by Biogen in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-05 Enrollment: 81 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07219043
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)81 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07219043
Protocol FieldVerified Registry Value
NCT IdentifierNCT07219043
Consolidated Lead SponsorBiogen
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment81 participants (ESTIMATED)
Registered Start Date2026-01-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Biogen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI